Anemia bone marrow changes

SAFETY PROFILE Poison by intraperitoneal and subcutaneous routes. An experimental teratogen. Human systemic effects by ingestion and intravenous route anorexia, nausea or vomiting, leukopenia, agranulocytosis and aplastic anemia of the blood, bone marrow changes, and hair changes. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of SOx. 

Linezolid has been associated with reversible myelosup-pression (14), which appears to be related to the duration of therapy, with a higher risk after more than 2 consecutive weeks of treatment (15). Myelosuppression with red cell hypoplasia has been reported in three patients taking linezolid 600 mg bd. The bone marrow changes were similar to those seen in reversible chloramphenicol toxicity. Another patient had sideroblastic anemia after taking linezolid for 2 months (16,17). 

Chronic effects associated with occupational exposures to turpentine include cerebral atrophy, behavioral changes, anemia, bone marrow damage, glomerulonephritis, and dermatitis. Urinary disturbances, albuminuria, and urinary casts were observed in workers exposed to paints and varnishes. Elowever, renal damage associated with occupational exposures to turpentine was transient and reversible. 

SY Anoxia unpleasant taste anemia methemo in animals hema spleen, kidney, bone marrow changes repro effects [care]... 

Toxicology LD50 (oral, rat) > 5000 mg/kg, (skin, rat) > 5 g/kg, (IP, rat) > 1 g/kg, (subcut., rat) > 1 g/kg LC50 (inh., rat) > 94,500 pg/m may cause normocytic anemia, bone marrow and spleen changes, changes in kidney or liver wt., renal failure reproductive effector Uses Herbicide for control of grass weed Trade Name Synonyms Hinochloa t[Bayer CropScience AG... 

Other adverse reactions associated with penicillin are hematopoietic changes such as anemia, thrombocytopenia (low platelet count), leukopenia (low white blood cell count), and bone marrow depression. When penicillin is given orally, glossitis (inflammation of the tongue), stomatitis (inflammation of die mouth), dry mouth, gastritis, nausea, vomiting, and abdominal pain occur. When penicillin is given intramuscularly (IM), there may be pain at die injection site Irritation of the vein and phlebitis (inflammation of a vein) may occur witii intravenous (IV) administration. 

The dose-limiting and most common adverse effect wdth intravenous and oral ganciclovir is bone marrow suppression (anemia, leukopenia, neutropenia, and thrombocytopenia). These effects are usually reversible upon w ithdraw al of the drug. CNS side effects are less common and range in severity from headache to behavioral changes to convulsions and coma. Fever, edema, phlebitis, disorientation, nausea, anorexia, rash, and myalgias have also been reported w ith ganciclovir therapy (Markham and Faulds, 1994). 

P. Veng-Pedersen, S. Chapel, N. H. Al-Huniti, R. L. Schmidt, E. M. Sedars, R. J. Hohl, and J. A. Widness, Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 25(4) 149-156 (2003). 

Suboptimal erythropoiesis can be classified by changes in the size of RBCs noted on examination of the peripheral blood. Because the excretory and endocrine functions of the kidney usually mirror each other, renal dysfunction can lead to anemia by reduction in EPO production, resulting in a normochromic, normocytic pattern. Other causes of insufficient erythropoiesis include replacement of bone marrow by fibrosis, solid tumors, or leukemia, as well as defects in erythroid maturation. Relative deficiencies in the cofactors required for heme-RBC synthesis such as iron, folate, and vitamin B may also be important contributors. Structurally, RBC macrocytosis denotes defects in the maturation of the nucleus, whereas microcytosis is indicative of cytoplasmic defects (reduced hemoglobin synthesis). (A detailed description regarding the pathogenesis and treatment of anemic disorders is found in Chap. 99.)... 

---